Observational studyInternational journal of urology : official journal of the Japanese Urological Association2026

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Shuzo Hamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.